From the Departments of Neurology (L.S.L., H.A.) and Clinical Epidemiology (R.W.T.), Aarhus University Hospital; and Department of Neurology (S.H.S.), Odense University Hospital, Denmark.
Neurology. 2022 Apr 12;98(15):e1555-e1561. doi: 10.1212/WNL.0000000000200015. Epub 2022 Mar 2.
Cancer may increase the risk of developing Guillain-Barré syndrome (GBS) due to molecular mimicry or immunosuppression, but the exact relationship is unclear. We aimed to determine the association between incident cancer and the following risk of GBS development.
We conducted a nationwide population-based case-control study of all patients with first-time hospital-diagnosed GBS in Denmark between 1987 and 2016 and 10 age-, sex-, and index date-matched population controls per case. We identified incident cancer diagnoses between 6 months before and 2 months after the GBS index date. We used conditional logistic regression to compute odds ratios (ORs) as a measure of relative risk and performed stratified analyses to assess the impact of cancer on GBS risk in strata of calendar periods, sex, and age. In sensitivity analyses, to assess any potential risk of survival bias induced by including cancer diagnoses potentially made after GBS diagnosis, we examined incident cancers in both a broader exposure window (1 year before to 3 months after GBS index date) and a narrower window (6 months to 1 month before the GBS index date).
Of the 2,414 patients with GBS and 23,909 controls included, 49 cases (2.0%) and 138 controls (0.6%) had a recent cancer diagnosis, yielding a matched OR of 3.6 (95% CI 2.6-5.1) for GBS associated with cancer. Stratification by calendar time, sex, and age showed robust results for the association between cancer and GBS, with no major variations. Broadening and narrowing the exposure window produced slightly weakened associations of OR of 2.4 (95% CI 1.8-3.3) and 2.5 (95% CI 1.5-4.1), respectively. The GBS ORs were highest for cancers of the lymphatic and hematopoietic tissue (OR 7.2, 95% CI 2.9-18.0), respiratory tract (OR 5.6, 95% CI 2.7-11.9), prostate and other male genital organ (OR 5.0, 95% CI 2.1-11.6), and breast (OR 5.0, 95% CI 1.7-14.5) cancer.
In this large nationwide epidemiologic study, incident cancer was associated with a markedly increased risk of subsequent GBS development. The results suggest that as-yet unidentified factors present in several types of cancer drive this association.
癌症可能通过分子模拟或免疫抑制增加发生格林-巴利综合征(GBS)的风险,但确切关系尚不清楚。我们旨在确定初发癌症与以下 GBS 发病风险的关系。
我们开展了一项全国性基于人群的病例对照研究,纳入了丹麦在 1987 年至 2016 年间首次经医院诊断的 GBS 患者以及每位病例年龄、性别和索引日期匹配的 10 名人群对照。我们确定了在 GBS 索引日期前 6 个月至后 2 个月之间的新发癌症诊断。我们使用条件逻辑回归计算比值比(OR)作为相对风险的衡量指标,并进行分层分析以评估癌症对 GBS 风险的影响在日历时段、性别和年龄的分层中。在敏感性分析中,为评估纳入可能在 GBS 诊断后做出的癌症诊断对生存偏差的任何潜在风险,我们在更广泛的暴露窗口(GBS 索引日期前 1 年至 3 个月)和更窄的窗口(GBS 索引日期前 6 个月至 1 个月)中检查了新发癌症。
在 2414 名 GBS 患者和 23909 名对照中,49 例(2.0%)和 138 例(0.6%)有近期癌症诊断,导致癌症与 GBS 相关的匹配 OR 为 3.6(95%CI 2.6-5.1)。按时间、性别和年龄分层,癌症与 GBS 之间的关联具有稳健的结果,没有重大差异。扩大和缩小暴露窗口会使 OR 的关联稍弱,分别为 2.4(95%CI 1.8-3.3)和 2.5(95%CI 1.5-4.1)。与癌症相关的 GBS 的 OR 最高的是淋巴和造血组织(OR 7.2,95%CI 2.9-18.0)、呼吸道(OR 5.6,95%CI 2.7-11.9)、前列腺和其他男性生殖器官(OR 5.0,95%CI 2.1-11.6)和乳房(OR 5.0,95%CI 1.7-14.5)癌症。
在这项大型全国性流行病学研究中,初发癌症与随后发生 GBS 的风险显著增加相关。结果表明,目前尚不清楚几种癌症中存在的因素驱动了这种关联。